Abstract:NLR family pyrin domain containing protein (NLRP) 3 is part of the NLRP3 inflammasome complex which is formed between NLRP3, the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC), and pro-caspase 1 and is involved in the production and activation/processing of interleukin (IL)-1β by inflammatory cells such as monocytes, macrophages, and neutrophils in response to danger signals such as pathogen-associated molecular patterns and damage-associated molecular patterns. The discovery of an inflammasome complex being involved in the processing of IL-1β was identified in 2002 by several groups,[1] [2] [3] who identified two of the known inflammasomes—NLRP1 and NLRP3. The importance of the NLRP3 inflammasome has been demonstrated in various diseases, including atherosclerosis and cardiovascular disease (reviewed in Grebe et al[4] and Toldo and Abbate[5]), Alzheimer's disease (reviewed in McManus and Latz [6]), and other age-related diseases (reviewed in Liang et al[7]). While predominantly investigated within the context of monocytes, macrophages, and neutrophils, recent work has investigated the NRLP3 inflammasome and IL-1β in the context of nontraditional cells such as platelets.[8] [9] [10] [11] [12] [13] [14] [15] [16] Since the discovery of the inflammasome, the focus of the literature regarding NLRP3 has predominantly been on NLRP3 in the context of the inflammasome complex rather than the actions of the NLRP3 protein itself. In this issue, Chen et al[9] have demonstrated that the NLRP3 protein has an important role within platelets that is independent of the NLRP3 inflammasome complex ([Fig. 1]). Consistent with previous findings by Qiao et al,[13] NLRP3 deficiency, both systemic and platelet-specific, impairs hemostatic function. Additionally, the difference in bleeding time and clot formation was NLRP3 protein-dependent and NLRP3 inflammasome-independent as demonstrated by the lack of change in the ASC −/− and caspase-1 −/− knockout models. The NLRP3 protein, not NLRP3 inflammasome, promoted adhesion of platelets to both collagen and von Willebrand factor (vWF) under conditions of low and high shear. Absence of the NLRP3 protein led to a reduction in their binding affinity to vWF and additionally altered downstream signaling pathways of glycoprotein (GP) Ib-IX by reducing phosphorylation of key molecules. As Qiao et al[13] also reported, a reduction in aggregation in response to low concentrations of adenosine diphosphate, collagen, and thrombin was observed in the absence of NLRP3 (either NLRP3 −/− or with NLRP3 inhibitor, CY-09) that was not maintained in the presence of stronger agonist concentrations. Chen et al[9] have identified that the NLRP3 protein, in platelets, is an important link between the cAMP/PKA (cyclic adenosine monophosphate/protein kinase A) axis and the binding of GPIbα to either filamin A or 14-3-3ζ during activation of GPIb-IX. cAMP/PKA-dependent phosphorylation of NLRP3 occurs via the NACHT domain; however, when cAMP/PKA levels are reduced or absent, dephosphorylation/activation of NLRP3 occurs, leading to increased binding to filamin A (via the PYD domain) and 14-3-3ζ and a subsequent increase in binding affinity to vWF. They further demonstrated the importance of the NLRP3 protein independent of inflammasome assembly both in the systemic knockout and platelet specifically by demonstrating reduction in infarct volume and improved neurological assessment in a transient middle cerebral artery occlusion model and reduced thrombus weight and length in a deep vein thrombosis model, with these effects not occurring in the ASC −/− or caspase −/− knockout mouse models. The potential for NLRP3 as a therapeutic target[17] [18] is currently of considerable interest. MCC950, an NLRP3 inhibitor being widely investigated, targets the NACHT domain and prevents conformational change and activation of NLRP3,[19] thus inhibiting both the NLRP3 protein and inflammasome. Based on the findings of Chen et al,[9] inhibition of NLRP3 may assist in the treatment of thrombotic disorders as well as the expected anti-inflammatory effects of NLRP3 inhibition. While inhibition of the IL-1β pathways is attractive, excessive inhibition could lead to other complications such as severe infection/sepsis as observed in the CANTOS trial,[20] therefore, achieving a balance is important. Based on the present study, NLRP3 may not only be as effective as IL-1β suppression in dampening inflammatory atherosclerosis,[21] and it may also deserve further investigation as an antithrombotic target and may be beneficial in diseases such as deep vein thrombosis and stroke. Received: 09 September 2024 Accepted: 10 September 2024 Accepted Manuscript online: 11 September 2024 Ar -Abstract Truncated-

The novel bispecific anti-NLRP3 inflammasome antibody InflamAb inhibits atherosclerosis in apolipoprotein E-deficient mice

anti-interleukin-18 as therapy against atherosclerosis

NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.

The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages

Pharmacological Blockade of NLRP3 Inflammasome/IL-1β-Positive Loop Mitigates Endothelial Cell Senescence and Dysfunction

IL-1β Inhibition Partially Negates the Beneficial Effects of Diet-Induced Atherosclerosis Regression in Mice

NLRP3 Inflammasome Activation Controls Vascular Smooth Muscle Cells Phenotypic Switch in Atherosclerosis

NLRP3: More than an Inflammasome?

Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice

Immunization with the Gly1127-Cys1140 amino acid sequence of the LRP1 receptor reduces atherosclerosis in rabbits. Molecular, immunohistochemical and nuclear imaging studies

Leukemia inhibitory factor receptor inhibition reduces stenosis grade and total serum cholesterol levels in a mouse model for atherosclerosis

Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in Mice

Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice

Protective Role of Autophagy in NLRP3 Inflammasome Activation and Medial Thickening of Mouse Coronary Arteries

Extracellular NLRP3 inflammasome particles are internalized by human coronary artery smooth muscle cells and induce pro-atherogenic effects

Pharmacological Treatment with Annexin A1 Reduces Atherosclerotic Plaque Burden in LDLR-/- Mice on Western Type Diet

VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis

NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation

Systemic application of 3-methyladenine markedly inhibited atherosclerotic lesion in ApoE-/- mice by modulating autophagy, foam cell formation and immune-negative molecules

NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer’s Disease

Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio